Evolocumab vs Inclisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Evolocumab · Repatha
Marketed by Amgen
NCT01516879 · Phase 3 · completed
The study randomly assigned 905 participants to quadruple-blinded monthly evolocumab or placebo, with both groups continuing background lipid-lowering therapy. The primary endpoint was met, with a statistically significant difference in LDL-C change at week 52, but LDL-C is a surrogate laboratory endpoint rather than a clinical outcome.
Next expected readout: November 2026 · NCT06496243 (registry estimate)
Reported efficacy
Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08) (met)
Result source: NCT02392559
Inclisiran · Leqvio
Marketed by Novartis and partners
NCT03397121 · Phase 3 · completed
The trial randomly assigned 482 participants to double-blind inclisiran or placebo, with 242 receiving inclisiran and 240 receiving placebo. Both primary LDL-C comparisons were statistically significant in favor of inclisiran, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical outcome, supporting a moderate evidence grade.
Next expected readout: November 2026 · NCT06501443 (registry estimate)
Reported efficacy
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78) (met)
Result source: NCT04652726
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Evolocumab | Inclisiran |
|---|---|---|
| LDL-C, % change | -50.1% vs 6.8%−57 vs placeboNCT0151687957 other results
| -49.3% vs 4.2%−53.5 vs placeboNCT0340080076 other results
|
| Non-HDL-C, % change | -41.8% vs 8.4%−50.3 vs placeboNCT0151687950 other results
| -41.2% vs 2.1%−43.3 vs placeboNCT0340080038 other results
|
| ApoB, % change | -41.3% vs 2.9%−44.2 vs placeboNCT0151687953 other results
| -38.1% vs 0.8%−38.9 vs placeboNCT0340080038 other results
|
| Lp(a), % change | -27.7% vs -5.4%−22.3 vs placeboNCT0151687952 other results
| -9.3% vs 3.6%−12.9 vs placeboNCT0465272634 other results
|
| 3-point MACE (% with event) | 7.9% vs 9.9%−2 vs placeboNCT017646335 other results
| —Not posted · NCT05004675 |
LDL-C, % change
- Evolocumab
- -50.1% vs 6.8%−57 vs placeboNCT01516879
57 other results
- -44.5% vs -6.2% NCT02392559
- -55.2% vs 1.7% NCT02833844
- -61.6% vs 8.1% NCT01763866
- -58.2% vs 8.1% NCT01763866
- -61.8% vs 8.1% NCT01763866
- -58.7% vs 8.1% NCT01763866
- -60.1% vs 8.1% NCT01763866
- -59.4% vs 8.1% NCT01763866
- -58.9% vs 8.1% NCT01763866
- -52.4% vs 8.1% NCT01763866
- -65.9% vs 8.1% NCT01763866
- -57.0% vs 8.1% NCT01763866
- -57.0% vs -1.3% NCT01763827
- -56.1% vs -1.3% NCT01763827
- -62.3% vs 7.1% NCT02662569
- -54.3% vs -1.1% NCT02739984
- -69.0% vs 4.9% NCT02662569
- -61.3% vs 5.5% NCT01763918
- -55.7% vs 5.5% NCT01763918
- -64.7% vs 7.1% NCT02662569
- -73.6% vs 1.4% NCT01953328
- -64.6% vs 1.4% NCT01953328
- -74.5% vs 1.4% NCT01953328
- -70.4% vs 1.4% NCT01953328
- -73.7% vs -0.4% NCT01953328
- -70.0% vs -0.4% NCT01953328
- -74.8% vs -0.4% NCT01953328
- -76.9% vs -0.4% NCT01953328
- -61.4% vs 7.5% NCT01763866
- -62.5% vs 7.5% NCT01763866
- -61.8% vs 7.5% NCT01763866
- -65.0% vs 7.5% NCT01763866
- -59.3% vs 7.5% NCT01763866
- -63.8% vs 7.5% NCT01763866
- -59.1% vs 7.5% NCT01763866
- -62.9% vs 7.5% NCT01763866
- -66.2% vs 7.5% NCT01763866
- -62.5% vs 7.5% NCT01763866
- -56.9% vs -1.4% NCT01763827
- -58.8% vs -1.4% NCT01763827
- -61.2% vs 2.3% NCT01763918
- -63.3% vs 2.3% NCT01763918
- -65.3% vs 4.9% NCT02662569
- -65.0% vs -0.8% NCT02739984
- -23.1% vs 7.9% NCT01588496
- -52.8% vs -16.7% NCT01984424
- -56.1% vs -18.1% NCT01763905
- -52.6% vs -18.1% NCT01763905
- -54.5% vs -16.7% NCT01984424
- -56.1% vs -19.2% NCT01763905
- -55.3% vs -19.2% NCT01763905
- -54.4% vs 3.2% NCT01516879
- -59.0% vs 1.6% NCT02729025
- -48.0% vs -5.9% NCT02392559
- -57.8% vs -0.7% NCT02189837
- -83.2% vs -0.7% NCT02189837
- -25.6% vs 4.2% NCT01588496
- Inclisiran
- -49.3% vs 4.2%−53.5 vs placeboNCT03400800
76 other results
- -56.3% vs 1.3% NCT03399370
- -45.8% vs 3.4% NCT03400800
- -51.3% vs 2.5% NCT03399370
- -41.1% vs 8.4% NCT03397121
- -27.1% vs 1.4% NCT04652726
- -45.9% vs 1.6% NCT05888103
- -38.1% vs 6.2% NCT03397121
- 0.7% vs 2.4% NCT03851705
- -21.6% vs 11.7% NCT04659863
- -45.6% vs 1.4% NCT04873934
- -60% vs -7% NCT04929249
- -26.1% vs 1.5% NCT04652726
- -26.0% vs 3.3% NCT04652726
- -27.8% vs 1.5% NCT04652726
- -19% vs 2.1% NCT04652726
- -7.2% vs -1.5% NCT03851705
- -32.5% vs 6.4% NCT04652726
- 1.8% vs -2.9% NCT03851705
- -23.9% vs -0.1% NCT04652726
- -8.7% vs 3.3% NCT03851705
- -19.3% vs 5.4% NCT04659863
- -21.6% vs 11.7% NCT04659863
- -17.3% vs 10.2% NCT04659863
- -24.1% vs 17% NCT04659863
- -26.1% vs 6.8% NCT04659863
- -44.3% vs 2.4% NCT04873934
- -57.2% vs -2.8% NCT04929249
- -56.3% vs 9% NCT04666298
- -38.4% vs 2.1% NCT02597127
- -52.6% vs 2.1% NCT02597127
- -41.9% vs 2.1% NCT02597127
- -51.9% vs 9% NCT04666298
- -27.9% vs 2.1% NCT02597127
- -44.9% vs 2.1% NCT02597127
- -47.6% vs 9% NCT04666298
- -35.5% vs 2.1% NCT02597127
- -59.5% vs -24.3% NCT05192941
- -35.4% vs 1.4% NCT02597127
- -50.5% vs 1.4% NCT02597127
- -66.2% vs 4.3% NCT04666298
- -67.2% vs 2.3% NCT04666298
- -43.3% vs -0.9% NCT02597127
- -54.7% vs -0.9% NCT02597127
- -65.7% vs 1.2% NCT04666298
- -61.5% vs 2.7% NCT04666298
- -62.4% vs 0.2% NCT04666298
- -50.9% vs -4.3% NCT02597127
- -51.0% vs -4.3% NCT02597127
- -62.8% vs 1.3% NCT04666298
- -47.6% vs 1.7% NCT04666298
- -39.2% vs 1.4% NCT02597127
- -46.4% vs -0.9% NCT02597127
- -49.6% vs -4.3% NCT02597127
- -29.0% vs 1.4% NCT02597127
- -42.6% vs 1.4% NCT02597127
- -60.5% vs 4.3% NCT04666298
- -62.0% vs 2.3% NCT04666298
- -36.9% vs -0.9% NCT02597127
- -49.5% vs -0.9% NCT02597127
- -60.3% vs 1.2% NCT04666298
- -53.9% vs 2.7% NCT04666298
- -55.6% vs 0.2% NCT04666298
- -44.3% vs -4.3% NCT02597127
- -44.3% vs -4.3% NCT02597127
- -55.5% vs 1.3% NCT04666298
- -42.1% vs 1.7% NCT04666298
- -31.7% vs 1.4% NCT02597127
- -55.5% vs 4.3% NCT04666298
- -54.9% vs 2.3% NCT04666298
- -41.4% vs -0.9% NCT02597127
- -53% vs 1.2% NCT04666298
- -46.4% vs 2.7% NCT04666298
- -50.1% vs 0.2% NCT04666298
- -35.7% vs -4.3% NCT02597127
- -52.2% vs 1.3% NCT04666298
- -37.1% vs 1.7% NCT04666298
Non-HDL-C, % change
- Evolocumab
- -41.8% vs 8.4%−50.3 vs placeboNCT01516879
50 other results
- -41.2% vs -6.1% NCT02392559
- -48.1% vs 2.9% NCT02833844
- -53.4% vs 7.9% NCT01763866
- -52.2% vs 7.9% NCT01763866
- -54.8% vs 7.9% NCT01763866
- -50.0% vs 7.9% NCT01763866
- -52.0% vs 7.9% NCT01763866
- -51.6% vs 7.9% NCT01763866
- -51.0% vs 7.9% NCT01763866
- -46.4% vs 7.9% NCT01763866
- -59.0% vs 7.9% NCT01763866
- -51.0% vs 7.9% NCT01763866
- -50.1% vs 1.5% NCT01763827
- -49.7% vs 1.5% NCT01763827
- -52.9% vs 5.9% NCT02662569
- -59.1% vs 4.3% NCT02662569
- -56.2% vs 5.3% NCT01763918
- -49.7% vs 5.3% NCT01763918
- -55.8% vs 5.9% NCT02662569
- -46.9% vs -0.6% NCT02739984
- -67.8% vs -0.1% NCT01953328
- -58.0% vs -0.1% NCT01953328
- -68.9% vs -0.1% NCT01953328
- -63.3% vs -0.1% NCT01953328
- -68.5% vs -1.6% NCT01953328
- -61.7% vs -1.6% NCT01953328
- -69.7% vs -1.6% NCT01953328
- -69.1% vs -1.6% NCT01953328
- -53.5% vs 7.0% NCT01763866
- -56.1% vs 7.0% NCT01763866
- -54.4% vs 7.0% NCT01763866
- -56.3% vs 7.0% NCT01763866
- -52.6% vs 7.0% NCT01763866
- -55.5% vs 7.0% NCT01763866
- -52.1% vs 7.0% NCT01763866
- -55.7% vs 7.0% NCT01763866
- -59.3% vs 7.0% NCT01763866
- -56.0% vs 7.0% NCT01763866
- -50.2% vs 1.3% NCT01763827
- -52.0% vs 1.3% NCT01763827
- -55.8% vs 2.7% NCT01763918
- -57.3% vs 2.7% NCT01763918
- -56.6% vs 4.3% NCT02662569
- -56.6% vs -0.1% NCT02739984
- -45.7% vs -14.6% NCT01984424
- -48.6% vs -16.5% NCT01763905
- -46.1% vs -16.5% NCT01763905
- -47.4% vs -14.4% NCT01984424
- -48.7% vs -17.2% NCT01763905
- -49.1% vs -17.2% NCT01763905
- Inclisiran
- -41.2% vs 2.1%−43.3 vs placeboNCT03400800
38 other results
- -47.4% vs -0.1% NCT03399370
- -34.9% vs 7.4% NCT03397121
- -24% vs 1.2% NCT04652726
- -25.0% vs 1.8% NCT04652726
- -25.7% vs 1.8% NCT04652726
- -6.2% vs -1.1% NCT03851705
- -29% vs 5.1% NCT04652726
- -40.7% vs -0.1% NCT05888103
- 1.3% vs -1.7% NCT03851705
- 0.4% vs 2.5% NCT03851705
- -7.2% vs 2.9% NCT03851705
- -20.1% vs 7.1% NCT04659863
- -23.3% vs 9.4% NCT04659863
- -24% vs 19% NCT04659863
- -54.0% vs 1.3% NCT04666298
- -56.8% vs 2.0% NCT04666298
- -58.7% vs 0.8% NCT04666298
- -57.7% vs 2.0% NCT04666298
- -53.2% vs 1.8% NCT04666298
- -54.1% vs 0.6% NCT04666298
- -54.2% vs 1.0% NCT04666298
- -41.2% vs 1.1% NCT04666298
- -50.1% vs 1.3% NCT04666298
- -52.9% vs 2.0% NCT04666298
- -53.5% vs 0.8% NCT04666298
- -52.0% vs 2.0% NCT04666298
- -47.2% vs 1.8% NCT04666298
- -48.2% vs 0.6% NCT04666298
- -48.0% vs 1.0% NCT04666298
- -35.7% vs 1.1% NCT04666298
- -44.8% vs 1.3% NCT04666298
- -47.9% vs 2.0% NCT04666298
- -48.2% vs 0.8% NCT04666298
- -46.1% vs 2.0% NCT04666298
- -39.8% vs 1.8% NCT04666298
- -43.4% vs 0.6% NCT04666298
- -44.7% vs 1.0% NCT04666298
- -31.4% vs 1.1% NCT04666298
ApoB, % change
- Evolocumab
- -41.3% vs 2.9%−44.2 vs placeboNCT01516879
53 other results
- -34.9% vs -2.4% NCT02392559
- -45.1% vs 2.6% NCT02833844
- -48.3% vs 3.3% NCT02729025
- -50.9% vs 6.3% NCT01763866
- -47.1% vs 6.3% NCT01763866
- -49.8% vs 6.3% NCT01763866
- -46.5% vs 6.3% NCT01763866
- -50.1% vs 6.3% NCT01763866
- -48.6% vs 6.3% NCT01763866
- -45.6% vs 6.3% NCT01763866
- -43.7% vs 6.3% NCT01763866
- -56.0% vs 6.3% NCT01763866
- -49.2% vs 6.3% NCT01763866
- -47.2% vs 1.8% NCT01763827
- -46.6% vs 1.8% NCT01763827
- -49.7% vs 3.2% NCT02662569
- -56.4% vs 2.0% NCT02662569
- -49.8% vs 4.6% NCT01763918
- -44.8% vs 4.6% NCT01763918
- -53.9% vs 3.2% NCT02662569
- -40.3% vs 1.8% NCT02739984
- -64.8% vs -2.5% NCT01953328
- -54.8% vs -2.5% NCT01953328
- -62.8% vs -2.5% NCT01953328
- -64.4% vs -4.3% NCT01953328
- -51.0% vs 5.1% NCT01763866
- -51.4% vs 5.1% NCT01763866
- -49.1% vs 5.1% NCT01763866
- -53.3% vs 5.1% NCT01763866
- -49.8% vs 5.1% NCT01763866
- -53.6% vs 5.1% NCT01763866
- -47.1% vs 5.1% NCT01763866
- -53.0% vs 5.1% NCT01763866
- -55.6% vs 5.1% NCT01763866
- -54.4% vs 5.1% NCT01763866
- -47.0% vs 1.5% NCT01763827
- -49.4% vs 1.5% NCT01763827
- -49.6% vs 2.2% NCT01763918
- -52.8% vs 2.2% NCT01763918
- -55.0% vs 2.0% NCT02662569
- -50.2% vs 2.3% NCT02739984
- -19.2% vs 4.0% NCT01588496
- -58.0% vs -2.5% NCT01953328
- -64.8% vs -4.3% NCT01953328
- -58.5% vs -4.3% NCT01953328
- -64.2% vs -4.3% NCT01953328
- -20.2% vs 2.6% NCT01588496
- -43.5% vs -11.7% NCT01984424
- -45.8% vs -12.9% NCT01763905
- -43.1% vs -12.9% NCT01763905
- -45.3% vs -11.4% NCT01984424
- -45.9% vs -13.7% NCT01763905
- -46.0% vs -13.7% NCT01763905
- Inclisiran
- -38.1% vs 0.8%−38.9 vs placeboNCT03400800
38 other results
- -44.8% vs -1.7% NCT03399370
- -33.1% vs 2.9% NCT03397121
- -19.3% vs 1.7% NCT04652726
- -21.5% vs 4.2% NCT04652726
- -21.9% vs 3.9% NCT04652726
- -5.8% vs 4.5% NCT03851705
- -25.1% vs 2.2% NCT04652726
- -36.6% vs 0.2% NCT05888103
- -0.7% vs 2.8% NCT03851705
- -0.8% vs 3.5% NCT03851705
- -6.4% vs 6.3% NCT03851705
- -14.8% vs 10.6% NCT04659863
- -18.5% vs 4.5% NCT04659863
- -20.3% vs 10% NCT04659863
- -46.8% vs 3.8% NCT04666298
- -50.4% vs 3.9% NCT04666298
- -51.9% vs 2.0% NCT04666298
- -51.9% vs 3.0% NCT04666298
- -46.8% vs 2.8% NCT04666298
- -48.5% vs 1.4% NCT04666298
- -48.8% vs 2.2% NCT04666298
- -37.1% vs 1.1% NCT04666298
- -44.5% vs 3.8% NCT04666298
- -46.7% vs 3.9% NCT04666298
- -48.2% vs 2.0% NCT04666298
- -47.0% vs 3.0% NCT04666298
- -42.0% vs 2.8% NCT04666298
- -44.5% vs 1.4% NCT04666298
- -44.0% vs 2.2% NCT04666298
- -32.5% vs 1.1% NCT04666298
- -38.6% vs 3.8% NCT04666298
- -42.8% vs 3.9% NCT04666298
- -43.4% vs 2.0% NCT04666298
- -40.9% vs 3.0% NCT04666298
- -35.8% vs 2.8% NCT04666298
- -39.9% vs 1.4% NCT04666298
- -39.7% vs 2.2% NCT04666298
- -28.2% vs 1.1% NCT04666298
Lp(a), % change
- Evolocumab
- -27.7% vs -5.4%−22.3 vs placeboNCT01516879
52 other results
- -16.4% vs 10.3% NCT02833844
- -12.8% vs 1.1% NCT02729025
- -25.9% vs 11.4% NCT01763866
- -20.3% vs 11.4% NCT01763866
- -24.6% vs 11.4% NCT01763866
- -24.7% vs 11.4% NCT01763866
- -25.1% vs 11.4% NCT01763866
- -20.9% vs 11.4% NCT01763866
- -26.1% vs 11.4% NCT01763866
- -22.0% vs 11.4% NCT01763866
- -38.1% vs 11.4% NCT01763866
- -29.2% vs 11.4% NCT01763866
- -20.4% vs 0% NCT01763827
- -17.8% vs 0% NCT01763827
- -25.2% vs 7.4% NCT02739984
- -42.3% vs 16.9% NCT02662569
- -22.9% vs 6.7% NCT01763918
- -21.6% vs 6.7% NCT01763918
- -35.9% vs 26.5% NCT02662569
- -37.9% vs 26.5% NCT02662569
- -45.7% vs 10.8% NCT01953328
- -41.7% vs 10.8% NCT01953328
- -41.9% vs 10.8% NCT01953328
- -45.7% vs 10.8% NCT01953328
- -45.0% vs 6.5% NCT01953328
- -49.5% vs 6.5% NCT01953328
- -26.0% vs 11.4% NCT01763866
- -22.6% vs 11.4% NCT01763866
- -24.0% vs 11.4% NCT01763866
- -27.5% vs 11.4% NCT01763866
- -24.3% vs 11.4% NCT01763866
- -23.2% vs 11.4% NCT01763866
- -25.0% vs 11.4% NCT01763866
- -25.9% vs 11.4% NCT01763866
- -38.6% vs 11.4% NCT01763866
- -32.2% vs 11.4% NCT01763866
- -18.4% vs 0% NCT01763827
- -19.2% vs 0% NCT01763827
- -24.0% vs 5.3% NCT01763918
- -25.6% vs 5.3% NCT01763918
- -38.6% vs 16.9% NCT02662569
- -30.9% vs 9.6% NCT02739984
- -9.4% vs 2.4% NCT01588496
- -46.0% vs 6.5% NCT01953328
- -43.0% vs 6.5% NCT01953328
- -12.7% vs -1.4% NCT01588496
- -21.1% vs 0.2% NCT01984424
- -27.0% vs -1.7% NCT01763905
- -22.1% vs -1.7% NCT01763905
- -22.7% vs -1.6% NCT01984424
- -26.2% vs -2.3% NCT01763905
- -23.7% vs -2.3% NCT01763905
- Inclisiran
- -9.3% vs 3.6%−12.9 vs placeboNCT04652726
34 other results
- -5.0% vs 1.1% NCT04652726
- -7.2% vs 1.1% NCT04652726
- -4.8% vs 4.9% NCT03851705
- -13.4% vs 5.4% NCT04652726
- -23.8% vs 6.4% NCT05888103
- -3.8% vs 15.2% NCT03851705
- -4.6% vs 4.3% NCT03851705
- -1.7% vs -12.1% NCT04659863
- -0.3% vs -16.5% NCT04659863
- -0.7% vs -4.4% NCT04659863
- -35.4% vs 5.5% NCT04666298
- -38.1% vs 4.0% NCT04666298
- -37.2% vs 0.2% NCT04666298
- -37.9% vs -2.4% NCT04666298
- -34.3% vs 4.3% NCT04666298
- -36.2% vs -4.3% NCT04666298
- -31.3% vs 0.9% NCT04666298
- -22.8% vs 3.3% NCT04666298
- -25.5% vs 5.5% NCT04666298
- -21.6% vs 4.0% NCT04666298
- -30.3% vs 0.2% NCT04666298
- -26.0% vs -2.4% NCT04666298
- -24.9% vs 4.3% NCT04666298
- -26.1% vs -4.3% NCT04666298
- -22.8% vs 0.9% NCT04666298
- -16.6% vs 3.3% NCT04666298
- -30.1% vs 5.5% NCT04666298
- -32.2% vs 4.0% NCT04666298
- -31.5% vs 0.2% NCT04666298
- -32.0% vs -2.4% NCT04666298
- -27.1% vs 4.3% NCT04666298
- -30.9% vs -4.3% NCT04666298
- -28.1% vs 0.9% NCT04666298
- -21.8% vs 3.3% NCT04666298
3-point MACE (% with event)
- Evolocumab
- 7.9% vs 9.9%−2 vs placeboNCT01764633
5 other results
- 6.7% vs 8.3% NCT01764633
- 5.5% vs 6.8% NCT01764633
- 4.3% vs 5.2% NCT01764633
- 3.1% vs 3.7% NCT01764633
- 1.6% vs 1.9% NCT01764633
- Inclisiran
- —Not posted · NCT05004675
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety
Coverage. Evolocumab: 16 of 16 rows · Inclisiran: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Evolocumab Rows use multiple source trials | Inclisiran Rows use multiple source trials |
|---|---|---|
| Apo B percent change · % of baseline No placebo or comparator arm | -22.68% (n=106) @ 216wka,b,c,d NCT01624142 · Phase 2/3 | -33.66% (n=277) @ 205.71wka,b,c,d NCT03060577 · Phase 2 · registry result, not featured evidence |
| HDL-C percent change · % of baseline | 5.77% (n=599) vs 0.35% (n=302) placebo @ 52wke,f,g NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 20 other source trials5.54% (n=110) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 7.66% (n=110) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 8.44% (n=109) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 7.76% (n=110) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 4.86% (n=111) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 6.35% (n=112) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 6.23% (n=113) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 7.72% (n=115) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 10.35% (n=112) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 6.71% (n=115) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 3.89% (n=153) vs -1.64% (n=76) placeboQ2W NCT01763827 · Phase 3 3.81% (n=153) vs -1.64% (n=76) placeboQM NCT01763827 · Phase 3 7.93% (n=110) vs -0.45% (n=54) placeboQ2W NCT01763918 · Phase 3 6.62% (n=110) vs -0.45% (n=54) placeboQM NCT01763918 · Phase 3 7.59% (n=325) vs 1.25% (n=164) placeboQ2W NCT02662569 · Phase 3 · registry result, not featured evidence 13.75% (n=332) vs 1.25% (n=164) placeboQM NCT02662569 · Phase 3 · registry result, not featured evidence 7.85% (n=145) vs 1.66% (n=73) Ezetimibe NCT01984424 · Phase 3 · registry result, not featured evidence 7.23% (n=280) vs -2.57% (n=141) placebo NCT02739984 · Phase 3 · registry result, not featured evidence 5.48% (n=103) vs 0.33% (n=51) EzetimibeQ2W NCT01763905 · Phase 3 · registry result, not featured evidence 7.18% (n=102) vs 0.33% (n=51) EzetimibeQM NCT01763905 · Phase 3 · registry result, not featured evidence | 4.4% (n=92) vs 0.9% (n=48) placebo @ 51.43wke,f,g NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| LDL-C absolute change · mg/dL | -52.7 vs 5.1 placebo mg/dL @ 52wkh,f NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 20 other source trials-76.8 vs 6.8 placebo mg/dLQ2W NCT01763866 · Phase 3 -80.1 vs 6.8 placebo mg/dLQM NCT01763866 · Phase 3 -58.8 vs 6.8 placebo mg/dLQ2W NCT01763866 · Phase 3 -60.1 vs 6.8 placebo mg/dLQM NCT01763866 · Phase 3 -52.3 vs 6.8 placebo mg/dLQ2W NCT01763866 · Phase 3 -55.3 vs 6.8 placebo mg/dLQM NCT01763866 · Phase 3 -68.9 vs 6.8 placebo mg/dLQ2W NCT01763866 · Phase 3 -77.8 vs 6.8 placebo mg/dLQM NCT01763866 · Phase 3 -83.8 vs 6.8 placebo mg/dLQ2W NCT01763866 · Phase 3 -78.4 vs 6.8 placebo mg/dLQM NCT01763866 · Phase 3 -78.4 vs 1.2 placebo mg/dLQ2W NCT01763827 · Phase 3 -81.9 vs 1.2 placebo mg/dLQM NCT01763827 · Phase 3 -101.7 vs -6.5 placebo mg/dLQ2W NCT01763918 · Phase 3 -98.8 vs -6.5 placebo mg/dLQM NCT01763918 · Phase 3 -64.6 vs -2.1 placebo mg/dLQ2W NCT02662569 · Phase 3 · registry result, not featured evidence -71.9 vs -2.1 placebo mg/dLQM NCT02662569 · Phase 3 · registry result, not featured evidence -106.8 vs -31 Ezetimibe mg/dL NCT01984424 · Phase 3 · registry result, not featured evidence -75.5 vs -8.3 placebo mg/dL NCT02739984 · Phase 3 · registry result, not featured evidence -105.4 vs -39.1 Ezetimibe mg/dLQ2W NCT01763905 · Phase 3 · registry result, not featured evidence -103.6 vs -39.1 Ezetimibe mg/dLQM NCT01763905 · Phase 3 · registry result, not featured evidence | -50.91 vs 0.96 placebo mg/dL @ 72.9wki,h,f NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 1 more dose-48.63 vs 0.31 placebo mg/dL NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| LDL-C percent change · % of baseline No placebo or comparator arm | -32.22% (n=106) @ 216wka,b,c,d NCT01624142 · Phase 2/3 2 other source trials-64.5% (n=82) NCT01879319 · Phase 3 · registry result, not featured evidence -67.9% (n=82) NCT01879319 · Phase 3 · registry result, not featured evidence | -46.74% (n=277) @ 205.71wka,b,c,d NCT03060577 · Phase 2 · registry result, not featured evidence |
| LDL-C absolute change · mg/dL No placebo or comparator arm | -63.1 mg/dL @ 80wk420 mg QMi,j,b,c,k NCT02624869 · Phase 3 show 2 more doses-67.2 mg/dL @ 80wk420 mg QM NCT02624869 · Phase 3 -36.5 mg/dL @ 80wk420 mg QM NCT02624869 · Phase 3 | -60.04 mg/dL @ 205.71wkj,b,c,k NCT03060577 · Phase 2 · registry result, not featured evidence |
| LDL-C percent change · % of baseline Extension (open-label) No placebo or comparator arm | -47.94% (n=770) @ 104wkb,c,l NCT02304484 · Phase 3 · registry result, not featured evidence | -45.45% (n=103) @ 47.14wkb,c,l NCT05888103 · Phase 3 · registry result, not featured evidence |
| LDL-C Less Than 70 responder rate · % of participants | 88.1% (n=110) vs 5.7% (n=56) placeboQ2Wi,m,c,n NCT01763866 · Phase 3 show 9 more doses85.8% (n=110) vs 5.7% (n=56) placeboQM NCT01763866 · Phase 3 94.4% (n=109) vs 5.7% (n=56) placeboQ2W NCT01763866 · Phase 3 92.5% (n=110) vs 5.7% (n=56) placeboQM NCT01763866 · Phase 3 93.5% (n=111) vs 5.7% (n=56) placeboQ2W NCT01763866 · Phase 3 94.5% (n=112) vs 5.7% (n=56) placeboQM NCT01763866 · Phase 3 88.7% (n=113) vs 5.7% (n=56) placeboQ2W NCT01763866 · Phase 3 89.9% (n=115) vs 5.7% (n=56) placeboQM NCT01763866 · Phase 3 93.6% (n=112) vs 5.7% (n=56) placeboQ2W NCT01763866 · Phase 3 88.5% (n=115) vs 5.7% (n=56) placeboQM NCT01763866 · Phase 3 | 66.7% (n=201) vs 28.1% (n=199) Usual Care @ 47wkm,c,n NCT04873934 · Phase 3 · registry result, not featured evidence · combination 1 other source trial81.8% (n=225) vs 22.2% (n=225) Usual Care @ 47wk NCT04929249 · Phase 3 · registry result, not featured evidence |
| Lp(a percent change · % of baseline No placebo or comparator arm | -14.06% (n=106) @ 216wka,b,c,d NCT01624142 · Phase 2/3 | -5.24% (n=277) @ 205.71wka,b,c,d NCT03060577 · Phase 2 · registry result, not featured evidence |
| Non-HDL-C percent change · % of baseline No placebo or comparator arm | -31.4% (n=106) @ 216wko,b,c,p NCT01624142 · Phase 2/3 | -13% (n=13) @ 102.86wko,b,c,p NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 1 other source trial-5% (n=34) @ 102.86wk NCT03851705 · Phase 3 · registry result, not featured evidence |
| Total Cholesterol percent change · % of baseline | -28.18% (n=599) vs 5.26% (n=302) placebo @ 52wkh,f,q NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 4 other source trials-38.64% (n=325) vs 2.89% (n=164) placeboQ2W NCT02662569 · Phase 3 · registry result, not featured evidence -39.74% (n=332) vs 2.89% (n=164) placeboQM NCT02662569 · Phase 3 · registry result, not featured evidence -38.04% (n=145) vs -11.43% (n=73) Ezetimibe NCT01984424 · Phase 3 · registry result, not featured evidence -42.19% (n=280) vs -1.13% (n=141) placebo NCT02739984 · Phase 3 · registry result, not featured evidence | -28% (n=810) vs 1.79% (n=807) placebo @ 72.9wkh,f,q NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 1 other source trial-33.56% (n=781) vs -0.42% (n=781) placebo @ 72.9wk NCT03399370 · Phase 3 |
| Triglycerides percent change · % of baseline | -2.55% (n=599) vs 8.99% (n=302) placebo @ 52wke,f,g NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 20 other source trials-5.61% (n=110) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -13.38% (n=110) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -9.27% (n=109) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -6.36% (n=110) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -9.15% (n=111) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -15.43% (n=112) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -10.28% (n=113) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -7.26% (n=115) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -11.67% (n=112) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -15.93% (n=115) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -9.16% (n=153) vs -3.89% (n=76) placeboQ2W NCT01763827 · Phase 3 -15.71% (n=153) vs -3.89% (n=76) placeboQM NCT01763827 · Phase 3 -13.27% (n=110) vs 9.09% (n=54) placeboQ2W NCT01763918 · Phase 3 -9.25% (n=110) vs 9.09% (n=54) placeboQM NCT01763918 · Phase 3 -6.48% (n=325) vs 11.54% (n=164) placeboQ2W NCT02662569 · Phase 3 · registry result, not featured evidence -7.15% (n=332) vs 11.54% (n=164) placeboQM NCT02662569 · Phase 3 · registry result, not featured evidence -5.39% (n=145) vs -0.95% (n=73) Ezetimibe NCT01984424 · Phase 3 · registry result, not featured evidence -12.64% (n=280) vs 6.61% (n=141) placebo NCT02739984 · Phase 3 · registry result, not featured evidence -6.32% (n=103) vs -3.74% (n=51) EzetimibeQ2W NCT01763905 · Phase 3 · registry result, not featured evidence -6.73% (n=102) vs -3.74% (n=51) EzetimibeQM NCT01763905 · Phase 3 · registry result, not featured evidence | 1.7% (n=92) vs 3.8% (n=48) placebo @ 51.43wke,f,g NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| VLDL-C percent change · % of baseline | 2.74% (n=599) vs 31.89% (n=302) placebo @ 52wke,f,g NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 20 other source trials-6.85% (n=110) vs 6.51% (n=56) placeboQ2W NCT01763866 · Phase 3 -11.77% (n=110) vs 6.51% (n=56) placeboQM NCT01763866 · Phase 3 -8.96% (n=109) vs 6.51% (n=56) placeboQ2W NCT01763866 · Phase 3 -6.38% (n=110) vs 6.51% (n=56) placeboQM NCT01763866 · Phase 3 -9.09% (n=111) vs 6.51% (n=56) placeboQ2W NCT01763866 · Phase 3 -15.05% (n=112) vs 6.51% (n=56) placeboQM NCT01763866 · Phase 3 -12.22% (n=113) vs 6.51% (n=56) placeboQ2W NCT01763866 · Phase 3 -7.25% (n=115) vs 6.51% (n=56) placeboQM NCT01763866 · Phase 3 -14.57% (n=112) vs 6.51% (n=56) placeboQ2W NCT01763866 · Phase 3 -16.5% (n=115) vs 6.51% (n=56) placeboQM NCT01763866 · Phase 3 -8.4% (n=153) vs -3.81% (n=76) placeboQ2W NCT01763827 · Phase 3 -16.17% (n=153) vs -3.81% (n=76) placeboQM NCT01763827 · Phase 3 -13.97% (n=110) vs 8.66% (n=54) placeboQ2W NCT01763918 · Phase 3 -9.2% (n=110) vs 8.66% (n=54) placeboQM NCT01763918 · Phase 3 -17.55% (n=325) vs 9.63% (n=164) placeboQ2W NCT02662569 · Phase 3 · registry result, not featured evidence -16.09% (n=332) vs 9.63% (n=164) placeboQM NCT02662569 · Phase 3 · registry result, not featured evidence -6.81% (n=145) vs -2.15% (n=73) Ezetimibe NCT01984424 · Phase 3 · registry result, not featured evidence -13.64% (n=280) vs 3.42% (n=141) placebo NCT02739984 · Phase 3 · registry result, not featured evidence -7.6% (n=103) vs -5.76% (n=51) EzetimibeQ2W NCT01763905 · Phase 3 · registry result, not featured evidence -6.46% (n=102) vs -5.76% (n=51) EzetimibeQM NCT01763905 · Phase 3 · registry result, not featured evidence | 1% (n=92) vs 4.7% (n=48) placebo @ 51.43wke,f,g NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| Dropout rate | 5.6%r NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 64 more results0%Part A: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0.7% NCT01764633 · Phase 3 3.2% NCT02207634 · Phase 3 1.8%Q2W NCT01763866 · Phase 3 2.7%QM NCT01763866 · Phase 3 7.3%Q2W NCT01763866 · Phase 3 1.8%QM NCT01763866 · Phase 3 5.4%Q2W NCT01763866 · Phase 3 1.8%QM NCT01763866 · Phase 3 10.5%Q2W NCT01763866 · Phase 3 2.6%QM NCT01763866 · Phase 3 2.7%Q2W NCT01763866 · Phase 3 1.7%QM NCT01763866 · Phase 3 3.9%Q2W NCT01763827 · Phase 3 1.3%QM NCT01763827 · Phase 3 9%Q2W NCT01763918 · Phase 3 1.8%QM NCT01763918 · Phase 3 1%420 mg QM NCT02392559 · Phase 3 —420 mg QM NCT02392559 · Phase 3 30.2% NCT01624142 · Phase 2/3 3%420 mg QM NCT02624869 · Phase 3 2%420 mg QM NCT02624869 · Phase 3 15.4%420 mg QM NCT02624869 · Phase 3 38.3% NCT04608474 · Phase 4 · registry result, not featured evidence 0%HPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 0%NPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 3.3% NCT03403374 · Phase 4 · registry result, not featured evidence 14.5% NCT03689946 · Phase 3 · registry result, not featured evidence 16.4%Once Every 2 Weeks (Q2W) or Once a Month (QM) NCT02867813 · Phase 3 · registry result, not featured evidence —Evolocumab in Parent Study NCT02867813 · Phase 3 · registry result, not featured evidence 3.7% NCT03570697 · Phase 3 · registry result, not featured evidence — NCT02833844 · Phase 3 · registry result, not featured evidence 2.6%Evolocumab + Standard of Care NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Year 1: Evolocumab + Standard of C NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: Evolocumab + SOC / Evol NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: SOC / Evolocumab + SOC NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT02634580 · Phase 3 · registry result, not featured evidence —QM NCT02634580 · Phase 3 · registry result, not featured evidence 1.5%420 mg QM NCT02729025 · Phase 3 · registry result, not featured evidence 3.2% NCT02304484 · Phase 3 · registry result, not featured evidence 1.8%Q2W NCT02662569 · Phase 3 · registry result, not featured evidence 1.2%QM NCT02662569 · Phase 3 · registry result, not featured evidence 4.8% NCT01984424 · Phase 3 · registry result, not featured evidence 0.7% NCT02739984 · Phase 3 · registry result, not featured evidence 3.3% NCT01813422 · Phase 3 · registry result, not featured evidence 13%Evolocumab NCT02189837 · Phase 3 · registry result, not featured evidence 9.5%Evolocumab and Atorvastatin NCT02189837 · Phase 3 · registry result, not featured evidence · combination 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 0%QM NCT01953328 · Phase 3 · registry result, not featured evidence 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 0%QM NCT01953328 · Phase 3 · registry result, not featured evidence 8.7%Q2W NCT01763905 · Phase 3 · registry result, not featured evidence 1%QM NCT01763905 · Phase 3 · registry result, not featured evidence 6.1%Evolocumab AI/Pen NCT01879319 · Phase 3 · registry result, not featured evidence 2.4%Evolocumab AMD NCT01879319 · Phase 3 · registry result, not featured evidence 5.4%Evolocumab AI/Pen NCT01849497 · Phase 3 · registry result, not featured evidence 1.3%Evolocumab PFS NCT01849497 · Phase 3 · registry result, not featured evidence —All-IP Period: Evolocumab + SOC / NCT01439880 · Phase 2 · registry result, not featured evidence —All-IP Period: SOC / Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence 6.8%Evolocumab + SOC NCT01439880 · Phase 2 · registry result, not featured evidence · combination —SOC-controlled Period: Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence · combination | 2.9%s NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 46 more results—Part 1 - Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.2%Part 1- Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 4.7% NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 7.7% NCT03399370 · Phase 3 2% NCT05192941 · Phase 4 · registry result, not featured evidence 2.9%Inclisiran - Inclisiran NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Core Part NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Extension NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran + Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 9%Inclisiran With Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 5.7% NCT05763875 · Phase 3 · registry result, not featured evidence 5.8% NCT04929249 · Phase 3 · registry result, not featured evidence 100%ORION-3 Rollover NCT03814187 · Phase 3 · registry result, not featured evidence 17.6%Phase III Inclisiran-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 18.8%Phase III Placebo-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 16.8%Inclisiran NCT04807400 · Phase 3 · registry result, not featured evidence 15.2%Inclisiran + BS NCT04807400 · Phase 3 · registry result, not featured evidence · combination 8.1%Part 1 - Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 1: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence 4%300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence 1%200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence 0%100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —Inclisiran Only Arm NCT03060577 · Phase 2 · registry result, not featured evidence 19.7%Inclisiran-only NCT03060577 · Phase 2 · registry result, not featured evidence —Switching Arm After Day 360 Visit NCT03060577 · Phase 2 · registry result, not featured evidence 55.6% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 6.6%300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 4.8%300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 12.1%500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 6.3%200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 1.7%200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 8.1%100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —r NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 64 more results—Part A: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 — NCT01764633 · Phase 3 — NCT02207634 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763827 · Phase 3 —QM NCT01763827 · Phase 3 —Q2W NCT01763918 · Phase 3 —QM NCT01763918 · Phase 3 —420 mg QM NCT02392559 · Phase 3 —420 mg QM NCT02392559 · Phase 3 — NCT01624142 · Phase 2/3 —420 mg QM NCT02624869 · Phase 3 —420 mg QM NCT02624869 · Phase 3 —420 mg QM NCT02624869 · Phase 3 6.2% NCT04608474 · Phase 4 · registry result, not featured evidence —HPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence —NPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence — NCT03403374 · Phase 4 · registry result, not featured evidence — NCT03689946 · Phase 3 · registry result, not featured evidence —Once Every 2 Weeks (Q2W) or Once a Month (QM) NCT02867813 · Phase 3 · registry result, not featured evidence —Evolocumab in Parent Study NCT02867813 · Phase 3 · registry result, not featured evidence — NCT03570697 · Phase 3 · registry result, not featured evidence — NCT02833844 · Phase 3 · registry result, not featured evidence —Evolocumab + Standard of Care NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Year 1: Evolocumab + Standard of C NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: Evolocumab + SOC / Evol NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: SOC / Evolocumab + SOC NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT02634580 · Phase 3 · registry result, not featured evidence —QM NCT02634580 · Phase 3 · registry result, not featured evidence —420 mg QM NCT02729025 · Phase 3 · registry result, not featured evidence — NCT02304484 · Phase 3 · registry result, not featured evidence —Q2W NCT02662569 · Phase 3 · registry result, not featured evidence —QM NCT02662569 · Phase 3 · registry result, not featured evidence — NCT01984424 · Phase 3 · registry result, not featured evidence — NCT02739984 · Phase 3 · registry result, not featured evidence — NCT01813422 · Phase 3 · registry result, not featured evidence —Evolocumab NCT02189837 · Phase 3 · registry result, not featured evidence —Evolocumab and Atorvastatin NCT02189837 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT01953328 · Phase 3 · registry result, not featured evidence —QM NCT01953328 · Phase 3 · registry result, not featured evidence —Q2W NCT01953328 · Phase 3 · registry result, not featured evidence —QM NCT01953328 · Phase 3 · registry result, not featured evidence —Q2W NCT01763905 · Phase 3 · registry result, not featured evidence —QM NCT01763905 · Phase 3 · registry result, not featured evidence —Evolocumab AI/Pen NCT01879319 · Phase 3 · registry result, not featured evidence —Evolocumab AMD NCT01879319 · Phase 3 · registry result, not featured evidence —Evolocumab AI/Pen NCT01849497 · Phase 3 · registry result, not featured evidence —Evolocumab PFS NCT01849497 · Phase 3 · registry result, not featured evidence —All-IP Period: Evolocumab + SOC / NCT01439880 · Phase 2 · registry result, not featured evidence —All-IP Period: SOC / Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence —Evolocumab + SOC NCT01439880 · Phase 2 · registry result, not featured evidence · combination —SOC-controlled Period: Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence · combination | —s NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 46 more results—Part 1 - Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1- Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 — NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 — NCT03399370 · Phase 3 0.3% NCT05192941 · Phase 4 · registry result, not featured evidence —Inclisiran - Inclisiran NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Core Part NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Extension NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran + Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 0%Inclisiran With Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 0.6% NCT05763875 · Phase 3 · registry result, not featured evidence 0.9% NCT04929249 · Phase 3 · registry result, not featured evidence 0%ORION-3 Rollover NCT03814187 · Phase 3 · registry result, not featured evidence 1.5%Phase III Inclisiran-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 1.6%Phase III Placebo-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 0.7%Inclisiran NCT04807400 · Phase 3 · registry result, not featured evidence 1%Inclisiran + BS NCT04807400 · Phase 3 · registry result, not featured evidence · combination —Part 1 - Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 1: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —Inclisiran Only Arm NCT03060577 · Phase 2 · registry result, not featured evidence 3.1%Inclisiran-only NCT03060577 · Phase 2 · registry result, not featured evidence —Switching Arm After Day 360 Visit NCT03060577 · Phase 2 · registry result, not featured evidence — NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.5%r NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 64 more results—Part A: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 24.8% NCT01764633 · Phase 3 21.6% NCT02207634 · Phase 3 3.6%Q2W NCT01763866 · Phase 3 1.8%QM NCT01763866 · Phase 3 2.8%Q2W NCT01763866 · Phase 3 0.9%QM NCT01763866 · Phase 3 0.9%Q2W NCT01763866 · Phase 3 2.7%QM NCT01763866 · Phase 3 2.7%Q2W NCT01763866 · Phase 3 2.6%QM NCT01763866 · Phase 3 1.8%Q2W NCT01763866 · Phase 3 0.9%QM NCT01763866 · Phase 3 2%Q2W NCT01763827 · Phase 3 0.7%QM NCT01763827 · Phase 3 2.7%Q2W NCT01763918 · Phase 3 3.6%QM NCT01763918 · Phase 3 —420 mg QM NCT02392559 · Phase 3 1%420 mg QM NCT02392559 · Phase 3 27.4% NCT01624142 · Phase 2/3 2%420 mg QM NCT02624869 · Phase 3 4.1%420 mg QM NCT02624869 · Phase 3 16.7%420 mg QM NCT02624869 · Phase 3 0% NCT04608474 · Phase 4 · registry result, not featured evidence 5.3%HPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 4.5%NPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 6.7% NCT03403374 · Phase 4 · registry result, not featured evidence 0% NCT03689946 · Phase 3 · registry result, not featured evidence —Once Every 2 Weeks (Q2W) or Once a Month (QM) NCT02867813 · Phase 3 · registry result, not featured evidence 41.8%Evolocumab in Parent Study NCT02867813 · Phase 3 · registry result, not featured evidence 16.3% NCT03570697 · Phase 3 · registry result, not featured evidence 3.3% NCT02833844 · Phase 3 · registry result, not featured evidence —Evolocumab + Standard of Care NCT01854918 · Phase 3 · registry result, not featured evidence · combination 7.9%Year 1: Evolocumab + Standard of C NCT01854918 · Phase 3 · registry result, not featured evidence · combination 14.4%Years 2-3: Evolocumab + SOC / Evol NCT01854918 · Phase 3 · registry result, not featured evidence · combination 15.1%Years 2-3: SOC / Evolocumab + SOC NCT01854918 · Phase 3 · registry result, not featured evidence · combination 0%Q2W NCT02634580 · Phase 3 · registry result, not featured evidence 0%QM NCT02634580 · Phase 3 · registry result, not featured evidence 3.1%420 mg QM NCT02729025 · Phase 3 · registry result, not featured evidence 19.9% NCT02304484 · Phase 3 · registry result, not featured evidence 3.1%Q2W NCT02662569 · Phase 3 · registry result, not featured evidence 6.6%QM NCT02662569 · Phase 3 · registry result, not featured evidence 6.2% NCT01984424 · Phase 3 · registry result, not featured evidence 5% NCT02739984 · Phase 3 · registry result, not featured evidence 27.9% NCT01813422 · Phase 3 · registry result, not featured evidence 0%Evolocumab NCT02189837 · Phase 3 · registry result, not featured evidence 5%Evolocumab and Atorvastatin NCT02189837 · Phase 3 · registry result, not featured evidence · combination 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 0%QM NCT01953328 · Phase 3 · registry result, not featured evidence 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 2%QM NCT01953328 · Phase 3 · registry result, not featured evidence 4.9%Q2W NCT01763905 · Phase 3 · registry result, not featured evidence 1%QM NCT01763905 · Phase 3 · registry result, not featured evidence 1.2%Evolocumab AI/Pen NCT01879319 · Phase 3 · registry result, not featured evidence 0%Evolocumab AMD NCT01879319 · Phase 3 · registry result, not featured evidence 2.7%Evolocumab AI/Pen NCT01849497 · Phase 3 · registry result, not featured evidence 4%Evolocumab PFS NCT01849497 · Phase 3 · registry result, not featured evidence 22%All-IP Period: Evolocumab + SOC / NCT01439880 · Phase 2 · registry result, not featured evidence 19.6%All-IP Period: SOC / Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence —Evolocumab + SOC NCT01439880 · Phase 2 · registry result, not featured evidence · combination 8.2%SOC-controlled Period: Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence · combination | 7.5%s NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 46 more results3.2%Part 1 - Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1- Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 0%Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 22.3% NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 22.4% NCT03399370 · Phase 3 16.4% NCT05192941 · Phase 4 · registry result, not featured evidence —Inclisiran - Inclisiran NCT05888103 · Phase 3 · registry result, not featured evidence 4.9%Inclisiran - Inclisiran: Core Part NCT05888103 · Phase 3 · registry result, not featured evidence 1%Inclisiran - Inclisiran: Extension NCT05888103 · Phase 3 · registry result, not featured evidence 15.8%Inclisiran + Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination —Inclisiran With Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 0.6% NCT05763875 · Phase 3 · registry result, not featured evidence 11.5% NCT04929249 · Phase 3 · registry result, not featured evidence 15.1%ORION-3 Rollover NCT03814187 · Phase 3 · registry result, not featured evidence 30.7%Phase III Inclisiran-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 32.6%Phase III Placebo-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 8.8%Inclisiran NCT04807400 · Phase 3 · registry result, not featured evidence 12.8%Inclisiran + BS NCT04807400 · Phase 3 · registry result, not featured evidence · combination —Part 1 - Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence 5.4%Part 1: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence 20.8%Part 2: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence 7.1%300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence 6.9%200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence 3.6%100 mg NCT04666298 · Phase 2 · registry result, not featured evidence 36.6%Inclisiran Only Arm NCT03060577 · Phase 2 · registry result, not featured evidence —Inclisiran-only NCT03060577 · Phase 2 · registry result, not featured evidence 34.5%Switching Arm After Day 360 Visit NCT03060577 · Phase 2 · registry result, not featured evidence 25% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy 14.8%300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 18%300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 12.3%500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 12.9%200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 18.3%200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 21.3%100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | r nasopharyngitis 10.5% (placebo 9.6%) upper respiratory tract infection 9.3% (placebo 6.3%) influenza 7.5% (placebo 6.3%) NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 54 more resultsbronchitis 12.5% (placebo 0%) dyspepsia 12.5% (placebo 0%) pain 12.5% (placebo 0%) NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 influenza 9.1% (placebo 0%) upper respiratory tract infection 9.1% (placebo 6.3%) gastroenteritis 6.1% (placebo 0%) NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 diabetes mellitus 8.4% (placebo 8%) hypertension 7.8% (placebo 8.4%) nasopharyngitis 7.7% (placebo 7.4%) NCT01764633 · Phase 3 nasopharyngitis 10.3% (placebo 7.5%) hypertension 6.2% (placebo 6.7%) back pain 5.9% (placebo 3.6%) NCT02207634 · Phase 3 Q2W muscle spasms 2.7% (placebo 0%) back pain 1.8% (placebo 0%) diarrhoea 1.8% (placebo 0%) NCT01763866 · Phase 3 QM muscle spasms 3.6% (placebo 0%) back pain 0.9% (placebo 0%) dizziness 0.9% (placebo 0%) NCT01763866 · Phase 3 Q2W diarrhoea 3.7% (placebo 0%) back pain 2.8% (placebo 0%) muscle spasms 1.8% (placebo 0%) NCT01763866 · Phase 3 QM headache 2.7% (placebo 1.8%) diarrhoea 1.8% (placebo 0%) myalgia 1.8% (placebo 3.6%) NCT01763866 · Phase 3 Q2W back pain 1.8% (placebo 0%) headache 1.8% (placebo 1.8%) myalgia 0.9% (placebo 3.6%) NCT01763866 · Phase 3 QM headache 2.7% (placebo 1.8%) back pain 0.9% (placebo 0%) diarrhoea 0.9% (placebo 0%) NCT01763866 · Phase 3 Q2W muscle spasms 1.8% (placebo 0%) back pain 0.9% (placebo 0%) constipation 0.9% (placebo 5.4%) NCT01763866 · Phase 3 QM back pain 1.7% (placebo 0%) diarrhoea 1.7% (placebo 0%) dizziness 1.7% (placebo 0%) NCT01763866 · Phase 3 Q2W back pain 5.4% (placebo 0%) dizziness 2.7% (placebo 0%) muscle spasms 2.7% (placebo 0%) NCT01763866 · Phase 3 QM headache 4.3% (placebo 1.8%) myalgia 2.6% (placebo 3.6%) back pain 1.7% (placebo 0%) NCT01763866 · Phase 3 Q2W headache 3.3% (placebo 3.9%) diarrhoea 2.6% (placebo 6.6%) nasopharyngitis 2% (placebo 1.3%) NCT01763827 · Phase 3 QM diarrhoea 3.3% (placebo 6.6%) headache 3.3% (placebo 3.9%) nasopharyngitis 2% (placebo 1.3%) NCT01763827 · Phase 3 Q2W nasopharyngitis 7.3% (placebo 3.7%) arthralgia 6.4% (placebo 1.9%) headache 3.6% (placebo 1.9%) NCT01763918 · Phase 3 QM nasopharyngitis 10% (placebo 3.7%) back pain 5.5% (placebo 0%) headache 4.5% (placebo 1.9%) NCT01763918 · Phase 3 420 mg QM nasopharyngitis 11.5% (placebo 11.3%) headache 10.6% (placebo 1.9%) oropharyngeal pain 6.7% (placebo 0%) NCT02392559 · Phase 3 allergic skin reaction 4.5% elevated creatine kinase 1.5% NCT04608474 · Phase 4 · registry result, not featured evidence angina pectoris 3.3% arthralgia 3.3% arthritis 3.3% NCT03403374 · Phase 4 · registry result, not featured evidence runny nose 5.5% NCT03689946 · Phase 3 · registry result, not featured evidence hypertension 14.2% (placebo 12.9%) bronchitis 6.9% (placebo 6.4%) upper respiratory tract infection 6.5% (placebo 8.2%) NCT02867813 · Phase 3 · registry result, not featured evidence hypertension 7.5% (placebo 6.2%) myalgia 6.3% (placebo 7.4%) angina pectoris 5% (placebo 8.6%) NCT03570697 · Phase 3 · registry result, not featured evidence back pain 3.9% (placebo 2.5%) influenza like illness 3.9% (placebo 2.5%) diarrhoea 3.6% (placebo 4.5%) NCT02833844 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.2% arthralgia 4.3% upper respiratory tract infection 4.2% NCT01854918 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.6% hypertension 7.5% upper respiratory tract infection 7.4% NCT01854918 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 12.6% upper respiratory tract infection 8.3% arthralgia 6.7% NCT01854918 · Phase 3 · registry result, not featured evidence · combination Q2W pharyngitis 15.8% abdominal distension 10.5% abdominal pain 5.3% NCT02634580 · Phase 3 · registry result, not featured evidence QM nasopharyngitis 23.8% hypertension 9.5% injection site pain 9.5% NCT02634580 · Phase 3 · registry result, not featured evidence 420 mg QM influenza 10.8% (placebo 4.7%) nasopharyngitis 9.2% (placebo 20.3%) myalgia 7.7% (placebo 1.6%) NCT02729025 · Phase 3 · registry result, not featured evidence hypertension 6.4% NCT02304484 · Phase 3 · registry result, not featured evidence Q2W diabetes mellitus 4.6% (placebo 1.2%) nasopharyngitis 2.8% (placebo 3.7%) upper respiratory tract infection 2.8% (placebo 3.7%) NCT02662569 · Phase 3 · registry result, not featured evidence QM diabetes mellitus 4.5% (placebo 1.2%) upper respiratory tract infection 3.9% (placebo 3.7%) nasopharyngitis 3.3% (placebo 3.7%) NCT02662569 · Phase 3 · registry result, not featured evidence myalgia 13.8% nasopharyngitis 9.7% arthralgia 9% NCT01984424 · Phase 3 · registry result, not featured evidence hypertension 3.9% (placebo 0%) diabetes mellitus 2.9% (placebo 3.5%) diarrhoea 2.1% (placebo 2.8%) NCT02739984 · Phase 3 · registry result, not featured evidence myalgia 7% (placebo 5.6%) chest pain 6.8% (placebo 5.4%) hypertension 6% (placebo 7%) NCT01813422 · Phase 3 · registry result, not featured evidence headache 36.4% (placebo 9.5%) influenza like illness 9.1% (placebo 0%) nasopharyngitis 9.1% (placebo 4.8%) NCT02189837 · Phase 3 · registry result, not featured evidence headache 35% (placebo 9.5%) myalgia 10% (placebo 4.8%) nausea 10% (placebo 4.8%) NCT02189837 · Phase 3 · registry result, not featured evidence · combination Q2W nasopharyngitis 13.7% (placebo 9.6%) diabetes mellitus 2% (placebo 0%) gastroenteritis 0% (placebo 1.9%) NCT01953328 · Phase 3 · registry result, not featured evidence QM nasopharyngitis 15.7% (placebo 9.6%) gastroenteritis 5.9% (placebo 1.9%) diabetes mellitus 3.9% (placebo 0%) NCT01953328 · Phase 3 · registry result, not featured evidence Q2W nasopharyngitis 24% (placebo 9.6%) diabetes mellitus 2% (placebo 0%) gastroenteritis 2% (placebo 1.9%) NCT01953328 · Phase 3 · registry result, not featured evidence QM nasopharyngitis 14% (placebo 9.6%) gastroenteritis 4% (placebo 1.9%) diabetes mellitus 0% (placebo 0%) NCT01953328 · Phase 3 · registry result, not featured evidence Q2W myalgia 6.8% muscle spasms 4.9% nasopharyngitis 4.9% NCT01763905 · Phase 3 · registry result, not featured evidence QM headache 11.8% pain in extremity 11.8% myalgia 8.8% NCT01763905 · Phase 3 · registry result, not featured evidence headache 2.7% NCT01849497 · Phase 3 · registry result, not featured evidence headache 5.3% NCT01849497 · Phase 3 · registry result, not featured evidence nasopharyngitis 28.7% upper respiratory tract infection 14.4% back pain 14.2% NCT01439880 · Phase 2 · registry result, not featured evidence nasopharyngitis 30.7% arthralgia 15.8% upper respiratory tract infection 14.3% NCT01439880 · Phase 2 · registry result, not featured evidence nasopharyngitis 16.8% upper respiratory tract infection 8.2% back pain 7% NCT01439880 · Phase 2 · registry result, not featured evidence · combination | s nasopharyngitis 11.6% (placebo 8.3%) injection site reaction 9.1% (placebo 0%) back pain 7.1% (placebo 4.2%) NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 30 more resultscovid-19 18.3% (placebo 25%) nasopharyngitis 14% (placebo 18.8%) headache 12.9% (placebo 6.3%) NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 covid-19 44.4% (placebo 25%) abdominal pain upper 22.2% (placebo 0%) injection site reaction 22.2% (placebo 0%) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 headache 15.4% (placebo 0%) influenza 15.4% (placebo 0%) abdominal pain upper 7.7% (placebo 0%) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 nasopharyngitis 11.2% (placebo 11.2%) diabetes mellitus 10.9% (placebo 11.7%) hypertension 6.5% (placebo 6.7%) NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 diabetes mellitus 15.4% (placebo 13.9%) bronchitis 5.9% (placebo 3.9%) hypertension 5.4% (placebo 5.4%) NCT03399370 · Phase 3 nasopharyngitis 8.2% (placebo 9.1%) covid-19 6.1% (placebo 6.3%) diabetes mellitus inadequate control 6.1% (placebo 5.6%) NCT05192941 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 24.3% (placebo 16.3%) blood glucose increased 9.7% (placebo 6.7%) blood creatine phosphokinase increased 6.8% (placebo 5.8%) NCT05888103 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 14% (placebo 16.3%) blood creatine phosphokinase increased 6% (placebo 5.8%) alanine aminotransferase increased 5% (placebo 2.9%) NCT05888103 · Phase 3 · registry result, not featured evidence covid-19 4.9% injection site pain 4.9% arthralgia 3.9% NCT04873934 · Phase 3 · registry result, not featured evidence · combination headache 3.4% (placebo 0%) nasopharyngitis 3.4% (placebo 3.4%) urinary tract infection 1.7% (placebo 2.3%) NCT05763875 · Phase 3 · registry result, not featured evidence covid-19 7.7% injection site pain 7.7% blood creatine phosphokinase increased 4.3% NCT04929249 · Phase 3 · registry result, not featured evidence covid-19 18.3% urinary tract infection 3.5% hypertension 3.2% NCT03814187 · Phase 3 · registry result, not featured evidence covid-19 11.8% diabetes mellitus inadequate control 7.5% hypertension 7% NCT03814187 · Phase 3 · registry result, not featured evidence covid-19 11.9% diabetes mellitus inadequate control 7.4% hypertension 7.4% NCT03814187 · Phase 3 · registry result, not featured evidence back pain 0.4% injection site rash 0.4% muscle spasms 0.4% NCT04807400 · Phase 3 · registry result, not featured evidence dizziness 0.4% rash 0.4% back pain 0% NCT04807400 · Phase 3 · registry result, not featured evidence · combination diarrhoea 5.4% (placebo 0%) pyrexia 5.4% (placebo 0%) respiratory tract infection viral 5.4% (placebo 10.5%) NCT03851705 · Phase 3 · registry result, not featured evidence corona virus infection 7.5% (placebo 0%) international normalised ratio increased 5.7% (placebo 0%) activated partial thromboplastin time prolonged 3.8% (placebo 0%) NCT03851705 · Phase 3 · registry result, not featured evidence 300 mg pyrexia 18.2% (placebo 12.3%) diabetes mellitus inadequate control 15.2% (placebo 15.8%) diabetes mellitus 12.1% (placebo 8.8%) NCT04666298 · Phase 2 · registry result, not featured evidence 200 mg diabetes mellitus 11.9% (placebo 8.8%) injection site reaction 11.9% (placebo 3.5%) pyrexia 11.9% (placebo 12.3%) NCT04666298 · Phase 2 · registry result, not featured evidence 100 mg diabetes mellitus 20% (placebo 8.8%) covid-19 14.5% (placebo 3.5%) pyrexia 14.5% (placebo 12.3%) NCT04666298 · Phase 2 · registry result, not featured evidence nasopharyngitis 19.4% (placebo 6.7%) hypertension 14.8% (placebo 2.2%) arthralgia 14.1% (placebo 11.1%) NCT03060577 · Phase 2 · registry result, not featured evidence hypertension 19.5% (placebo 2.2%) back pain 14.9% (placebo 1.1%) nasopharyngitis 14.9% (placebo 6.7%) NCT03060577 · Phase 2 · registry result, not featured evidence abdominal pain upper 25% acne 25% angina unstable 25% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy 300 mg double dose nasopharyngitis 18% (placebo 12.9%) musculoskeletal pain 9.8% (placebo 6.5%) diarrhoea 8.2% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence 300 mg single dose nasopharyngitis 14.8% (placebo 12.9%) cough 11.5% (placebo 4.8%) myalgia 9.8% (placebo 4.8%) NCT02597127 · Phase 2 · registry result, not featured evidence 500 mg single dose nasopharyngitis 13.8% (placebo 12.9%) influenza 7.7% (placebo 3.2%) upper respiratory tract infection 7.7% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence 200 mg double dose diarrhoea 11.3% (placebo 3.2%) cough 9.7% (placebo 4.8%) arthralgia 8.1% (placebo 1.6%) NCT02597127 · Phase 2 · registry result, not featured evidence 200 mg single dose nasopharyngitis 13.3% (placebo 12.9%) arthralgia 6.7% (placebo 1.6%) back pain 6.7% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence 100 mg double dose nasopharyngitis 13.1% (placebo 12.9%) myalgia 11.5% (placebo 4.8%) back pain 9.8% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2/3 versus Phase 2.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 216 weeks versus 205.71 weeks.
- ePopulation context differs: baseline_threshold differs (ldl_c>=75 versus ldl_c>130).
- fTreatment context differs: combination versus monotherapy.
- gAssessment timepoints differ: 52 weeks versus 51.43 weeks.
- hPopulation context differs: baseline_threshold differs (ldl_c>=75 versus ldl_c>=70); comorbidity_cardiovascular_disease differs (none recorded versus required); prior_therapy differs (experienced versus none recorded).
- iThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- jTrial phases differ: Phase 3 versus Phase 2.
- kAssessment timepoints differ: 80 weeks versus 205.71 weeks.
- lAssessment timepoints differ: 104 weeks versus 47.14 weeks.
- mPopulation comparability has not been reviewed for both studies.
- nThe assessment timepoint is not available for both results.
- oTrial phases differ: Phase 2/3 versus Phase 3.
- pAssessment timepoints differ: 216 weeks versus 102.86 weeks.
- qAssessment timepoints differ: 52 weeks versus 72.9 weeks.
- rPopulation comparability has not been reviewed for 60 of these studies.
- sPopulation comparability has not been reviewed for 40 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Evolocumab
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 11 more results
show 5 more results
show 5 more results
+ 21 further endpoints in the CSV export.
Inclisiran
show 6 more results
show 6 more results
show 6 more results
show 6 more results
show 2 more results
show 6 more results
show 5 more results
show 30 more results
show 6 more results
+ 42 further endpoints in the CSV export.
Homozygous Familial Hypercholesterolemia
Shared mechanism: PCSK9 · full Homozygous Familial Hypercholesterolemia pipeline
Evolocumab · Repatha
Marketed by Amgen
NCT01588496 · Phase 2/3 · completed
The randomized, quadruple-blind, placebo-controlled Part B (n=49) used a hard, regulator-accepted endpoint (LDL-C change from baseline) and the primary comparison was statistically significant and strongly favored evolocumab (LS mean difference -30.93%, 95% CI -43.86 to -18.00, p<0.001). Part A was an open-label single-arm pilot, but the grade is based on the randomized placebo-controlled Part B, which provides strong evidence for the drug.
Reported efficacy
Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12); Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12): Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001 (met)
Result source: NCT01588496
Inclisiran · Leqvio
Marketed by Novartis and partners
NCT04659863 · Phase 3 · completed
The first year was randomized, double-blind, and placebo-controlled, with 9 participants receiving inclisiran and 4 receiving placebo. The primary LDL-C endpoint was met, but the total sample of 13 was very small and underpowered for reliable generalization, so the findings provide limited evidence despite the favorable result.
Next expected readout: March 2028 · NCT06597006 (registry estimate)
Reported efficacy
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) (met)
Result source: NCT04659863
Results for Homozygous Familial Hypercholesterolemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Evolocumab: 7 of 8 rows · Inclisiran: 7 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Evolocumab | Inclisiran Rows use multiple source trials |
|---|---|---|
| Apo B percent change · % of baseline | -19.17% (n=33) vs 3.97% (n=16) placebo @ 12wka,b,c NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 1 more dose-20.24% (n=33) vs 2.65% (n=16) placebo NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 | -14.8% (n=9) vs 10.6% (n=4) placebo @ 51.43wkb,c NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
| Apo B percent change · % of baseline No placebo or comparator arm | -14.9% (n=8) @ 12wkb,d,e,f,g NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 1 other source trial-6% (n=29) @ 12wk NCT03403374 · Phase 4 · registry result, not featured evidence | -8% (n=34) @ 102.86wkb,d,e,f,g NCT03851705 · Phase 3 1 other source trial-7.3% (n=13) @ 102.86wk NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
| Lp(a percent change · % of baseline | -9.4% (n=33) vs 2.43% (n=16) placebo @ 12wka,b,c NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 1 more dose-12.71% (n=33) vs -1.43% (n=16) placebo NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 | -1.7% (n=9) vs -12.1% (n=4) placebo @ 51.43wkb,c NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
| Non-HDL-C percent change · % of baseline No placebo or comparator arm | -16.6% (n=8) @ 12wkb,d,e,f,g NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 | -5% (n=34) @ 102.86wkb,d,e,f,g NCT03851705 · Phase 3 1 other source trial-13% (n=13) @ 102.86wk NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
| Dropout rate | 0%Part A: Evolocumabh NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 4 more results—Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 3.3% NCT03403374 · Phase 4 · registry result, not featured evidence | 8.1%Part 1 - Inclisirani NCT03851705 · Phase 3 show 7 more results—Part 1: Inclisiran NCT03851705 · Phase 3 —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 —Part 2: Inclisiran NCT03851705 · Phase 3 —Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 55.6% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy |
| Discontinued due to AEs | —Part A: Evolocumabh NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 4 more results—Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 — NCT03403374 · Phase 4 · registry result, not featured evidence | —Part 1 - Inclisirani NCT03851705 · Phase 3 show 7 more results—Part 1: Inclisiran NCT03851705 · Phase 3 —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 —Part 2: Inclisiran NCT03851705 · Phase 3 —Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 — NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy |
| Serious AEs | —Part A: Evolocumabh NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 4 more results0%Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 6.7% NCT03403374 · Phase 4 · registry result, not featured evidence | —Part 1 - Inclisirani NCT03851705 · Phase 3 show 7 more results5.4%Part 1: Inclisiran NCT03851705 · Phase 3 —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 20.8%Part 2: Inclisiran NCT03851705 · Phase 3 0%Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 25% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy |
| Most frequent reported AEs | h bronchitis 12.5% (placebo 0%) dyspepsia 12.5% (placebo 0%) pain 12.5% (placebo 0%) NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 2 more resultsinfluenza 9.1% (placebo 0%) upper respiratory tract infection 9.1% (placebo 6.3%) gastroenteritis 6.1% (placebo 0%) NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 angina pectoris 3.3% arthralgia 3.3% arthritis 3.3% NCT03403374 · Phase 4 · registry result, not featured evidence | i diarrhoea 5.4% (placebo 0%) pyrexia 5.4% (placebo 0%) respiratory tract infection viral 5.4% (placebo 10.5%) NCT03851705 · Phase 3 show 4 more resultscorona virus infection 7.5% (placebo 0%) international normalised ratio increased 5.7% (placebo 0%) activated partial thromboplastin time prolonged 3.8% (placebo 0%) NCT03851705 · Phase 3 covid-19 44.4% (placebo 25%) abdominal pain upper 22.2% (placebo 0%) injection site reaction 22.2% (placebo 0%) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 headache 15.4% (placebo 0%) influenza 15.4% (placebo 0%) abdominal pain upper 7.7% (placebo 0%) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 abdominal pain upper 25% acne 25% angina unstable 25% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2/3 versus Phase 3.
- cPopulation context differs: baseline_threshold differs (ldl_c>=130 versus ldl_c>130).
- dOne study enrolled healthy volunteers and the other enrolled patients.
- ePopulation comparability has not been reviewed for both studies.
- fTreatment context has not been resolved for both arms.
- gAssessment timepoints differ: 12 weeks versus 102.86 weeks.
- hPopulation comparability has not been reviewed for 1 of these studies.
- iPopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Inclisiran
show 3 more results
show 2 more results
show 8 more results
show 8 more results
show 2 more results
show 8 more results
show 6 more results
show 2 more results
show 8 more results
show 2 more results
show 7 more results
show 2 more results
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evolocumab's landscape · Inclisiran's landscape